

FASKEN

Fasken Martineau DuMoulin LLP
Barristers and Solicitors
Patent and Trade-mark Agents

333 Bay Street, Suite 2400
P.O. Box 20
Toronto, Ontario M5H 2T6
Canada

T +1 416 366 8381
+1 800 268 8424
F +1 416 364 7813

fasken.com

October 22, 2019
File No.: 264476.00035

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: Algernon Pharmaceuticals Inc. (the “Issuer”)
Amended and Restated Short Form Prospectus dated October 22, 2019 (the
“Prospectus”)**

We refer to the Prospectus of the Issuer in relation to the offering of units of the Issuer.

We hereby consent to the reference to our firm name in the Introduction and under the headings “Interest of Experts” and “Legal Matters” and to the reference to our firm name and to the use of our opinion under the heading “Eligibility for Investment” in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations (as defined in the *Securities Act* (Ontario)) in the information contained in the Prospectus that is derived from our opinion referred to above or that is within our knowledge as a result of the services we performed in connection with such opinion.

This letter is delivered to the addressees pursuant to the requirements of Section 4.2(a)(vii) of National Instrument 44-101.

Yours truly,

“Fasken Martineau DuMoulin LLP”